The insulin pump treatment in the form of a continuous subcutaneous insulin infusion (CSII) - known for thirty years and nowadays proved to be safe and effective - is one of the potential and widely used methods of intensified therapy in type 1 diabetic patients. Evidences and meta-analyses confirm the favourable effect of pump treatment compared to multiple daily insulin injection regimens with a 0,2-0,7% decrease in the HbAlc value. The fall of the frequency of severe hypoglycaemias during the use of CSII reported earlier cannot be unequivocally proven today in the era of the modern conservative insulin regimens. The use of CSII might ameliorate quality of life, it might be a cost-effective form of therapy using properly and in the right persons. Its application has to be considered in well-educated type 1 diabetic patients with a higher than desirable HbAlc value despite aiming at normoglycaemia. The real-time continuous glucose monitoring augmented pump therapy might help in further improvement of glycaemic control in appropriately chosen patients. This technological development with "closing the loop" creates the possibility of an automatic glucoseregulation, the long-standing dream "artificial pancreas".
|Number of pages||8|
|Publication status||Published - dec. 1 2010|
- Continuous subcutaneous insulin infusion
- Evidence based
- Insulin pump
- Insulin treatment
ASJC Scopus subject areas